Tempus AI Validates HLA-LOH Assay in New Study Implications for Precision Medicine

Published | Modified August 8, 2024
CSIMarket Newsroom | CSIMarket.com

The Innovations in Precision Medicine: Tempus AI’s Groundbreaking Validation Study’

In a significant advancement for precision medicine, Tempus AI, Inc. (NASDAQ: TEM), a company at the forefront of integrating artificial intelligence in healthcare, has published groundbreaking findings related to its investigational human leukocyte antigen (HLA) loss of heterozygosity (LOH) assay. This research has been detailed in a recent article in ’npj Precision Oncology’, a peer-reviewed journal focused on cancer research and therapy.

Overview of the Study

The study

Sources for this article: Based on Tempus Ai Inc ’s official statement and Supply Chain Analysis by CSIMarket.com

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License